Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2523]

Pembrolizumab and lenvatinib receive positive EU CHMP opinions for two different types of cancer

Pembrolizumab and lenvatinib receive positive EU CHMP opinions for two different types of cancer

OPTIMA: New research project aims to improve treatment for patients with prostate, breast and lung cancer through artificial intelligence

OPTIMA: New research project aims to improve treatment for patients with prostate, breast and lung cancer through...

Gut bugs’ can drive prostate cancer growth and treatment resistance

Gut bugs’ can drive prostate cancer growth and treatment resistance

Androgen-producing gut microbes can derail prostate cancer treatment

Androgen-producing gut microbes can derail prostate cancer treatment

Olapirib in combination with abiraterone delayed disease progression in first line mCRPC

Olapirib in combination with abiraterone delayed disease progression in first line mCRPC

COVID-19 and cancer: Useful resources

COVID-19 and cancer: Useful resources

Study examines information and communication needs of men with prostate cancer

Study examines information and communication needs of men with prostate cancer

ESMO 2021: New combination of old drugs improves survival in patients with prostate cancer

ESMO 2021: New combination of old drugs improves survival in patients with prostate cancer

ESMO 2021: ARCHES study finds enzalutamide reduced risk of death by 34% in men with metastatic hormone-sensitive prostate cancer

ESMO 2021: ARCHES study finds enzalutamide reduced risk of death by 34% in men with metastatic hormone-sensitive...

ESMO 21: Patients and non-oncology doctors struggle to keep up with the pace of change in oncology, research shows

ESMO 21: Patients and non-oncology doctors struggle to keep up with the pace of change in oncology, research shows

More from ecancer